PUMA BIOTECHNOLOGY, INC. (PBYI) Guidance & Earnings Results

On 2026-08-06 PUMA BIOTECHNOLOGY, INC. raised guidance: "Raising 2026 revenue and net income…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 568.9M
P/E TTM: 21.2
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	Raising 2026 revenue and net income guidance · full year
7 May 26	Raised	FY2026 Total Revenue raised to $222-229M from $214-221M; FY2026 Net Income raised to $16-19M from $10-13M; Q2 2026 Net Product Revenue $50-52M; Q2 2026 Total Revenue $52-55M; Q2 2026 Net Income $2-4M; FY2026 Gross to Net Adjustment 26.5-27.5% (prior 27.5-28.5%) · full year
26 Feb 26	Reaffirmed	FY2026: Net Product Revenue $194-198M; Royalty Revenue $20-23M; Total Revenue $214-221M; Net Income $10-13M; Gross to Net Adjustment 27.5-28.5%. Q1 2026: Net Product Revenue $36-39M; Royalty Revenue $2-3M; Total Revenue $38-42M; Net Loss $(8)-(10)M. · full year
6 Nov 25	Raised	FY2025 net product revenue raised to $198-200M from $192-198M; royalty revenue raised to $22-23M from $20-24M; total revenue raised to $220-223M from $212-222M; net income raised to $27-29M from $23-28M; Gross to Net adjustment updated to 23-23.5% from 21.5-22%. · full year
7 Aug 25	Reaffirmed	FY25 net product revenue $192-198M; total revenue $212-222M; net income $23-28M; Q3 net product revenue $46-48M; total revenue $48-51M; net income $2-4M · full year

PUMA BIOTECHNOLOGY, INC. — questions

What guidance did PUMA BIOTECHNOLOGY, INC. give?: On 2026-08-06: "Raising 2026 revenue and net income guidance"
When does PUMA BIOTECHNOLOGY, INC. report earnings?: PUMA BIOTECHNOLOGY, INC.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.